United States Oncology Biosimilars Market Report 2017

Publisher Name :
Date: 03-Oct-2017
No. of pages: 104
Inquire Before Buying

In this report, the United States Oncology Biosimilars market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report splits the United States market into seven regions:

- The West

- Southwest

- The Middle Atlantic

- New England

- The South

- The Midwest

with sales (volume), revenue (value), market share and growth rate of Oncology Biosimilars in these regions, from 2012 to 2022 (forecast).

United States Oncology Biosimilars market competition by top manufacturers/players, with Oncology Biosimilars sales volume, price, revenue (Million USD) and market share for each manufacturer/player; the top players including

- Celltrion Inc.

- Pfizer Inc.

- Biocon

- BIOCAD

- Apotex Inc.

- Dr. Reddy's Laboratories Ltd.

- Sandoz International GmbH

- Intas Pharmaceuticals Ltd.

- STADA Arzneimittel AG

- Teva Pharmaceutical Industries Ltd.

On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into

- G-CSF

- Hematopoietic Agents

- Monoclonal Antibodies

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate of Oncology Biosimilars for each application, including

- Retail Pharmacies

- Hospital Pharmacies

- Online Pharmacies

If you have any special requirements, please let us know and we will offer you the report as you want.

United States Oncology Biosimilars Market Report 2017

Table of Contents
United States Oncology Biosimilars Market Report 2017
1 Oncology Biosimilars Overview
1.1 Product Overview and Scope of Oncology Biosimilars
1.2 Classification of Oncology Biosimilars by Product Category
1.2.1 United States Oncology Biosimilars Market Size (Sales Volume) Comparison by Type (2012-2022)
1.2.2 United States Oncology Biosimilars Market Size (Sales Volume) Market Share by Type (Product Category) in 2016
1.2.3 G-CSF
1.2.4 Hematopoietic Agents
1.2.5 Monoclonal Antibodies
1.3 United States Oncology Biosimilars Market by Application/End Users
1.3.1 United States Oncology Biosimilars Market Size (Consumption) and Market Share Comparison by Application (2012-2022)
1.3.2 Retail Pharmacies
1.3.3 Hospital Pharmacies
1.3.4 Online Pharmacies
1.4 United States Oncology Biosimilars Market by Region
1.4.1 United States Oncology Biosimilars Market Size (Value) Comparison by Region (2012-2022)
1.4.2 The West Oncology Biosimilars Status and Prospect (2012-2022)
1.4.3 Southwest Oncology Biosimilars Status and Prospect (2012-2022)
1.4.4 The Middle Atlantic Oncology Biosimilars Status and Prospect (2012-2022)
1.4.5 New England Oncology Biosimilars Status and Prospect (2012-2022)
1.4.6 The South Oncology Biosimilars Status and Prospect (2012-2022)
1.4.7 The Midwest Oncology Biosimilars Status and Prospect (2012-2022)
1.5 United States Market Size (Value and Volume) of Oncology Biosimilars (2012-2022)
1.5.1 United States Oncology Biosimilars Sales and Growth Rate (2012-2022)
1.5.2 United States Oncology Biosimilars Revenue and Growth Rate (2012-2022)
2 United States Oncology Biosimilars Market Competition by Players/Suppliers
2.1 United States Oncology Biosimilars Sales and Market Share of Key Players/Suppliers (2012-2017)
2.2 United States Oncology Biosimilars Revenue and Share by Players/Suppliers (2012-2017)
2.3 United States Oncology Biosimilars Average Price by Players/Suppliers (2012-2017)
2.4 United States Oncology Biosimilars Market Competitive Situation and Trends
2.4.1 United States Oncology Biosimilars Market Concentration Rate
2.4.2 United States Oncology Biosimilars Market Share of Top 3 and Top 5 Players/Suppliers
2.4.3 Mergers & Acquisitions, Expansion in United States Market
2.5 United States Players/Suppliers Oncology Biosimilars Manufacturing Base Distribution, Sales Area, Product Type
3 United States Oncology Biosimilars Sales (Volume) and Revenue (Value) by Region (2012-2017)
3.1 United States Oncology Biosimilars Sales and Market Share by Region (2012-2017)
3.2 United States Oncology Biosimilars Revenue and Market Share by Region (2012-2017)
3.3 United States Oncology Biosimilars Price by Region (2012-2017)
4 United States Oncology Biosimilars Sales (Volume) and Revenue (Value) by Type (Product Category) (2012-2017)
4.1 United States Oncology Biosimilars Sales and Market Share by Type (Product Category) (2012-2017)
4.2 United States Oncology Biosimilars Revenue and Market Share by Type (2012-2017)
4.3 United States Oncology Biosimilars Price by Type (2012-2017)
4.4 United States Oncology Biosimilars Sales Growth Rate by Type (2012-2017)
5 United States Oncology Biosimilars Sales (Volume) by Application (2012-2017)
5.1 United States Oncology Biosimilars Sales and Market Share by Application (2012-2017)
5.2 United States Oncology Biosimilars Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities
6 United States Oncology Biosimilars Players/Suppliers Profiles and Sales Data
6.1 Celltrion Inc.
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Oncology Biosimilars Product Category, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Celltrion Inc. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
6.1.4 Main Business/Business Overview
6.2 Pfizer Inc.
6.2.2 Oncology Biosimilars Product Category, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Pfizer Inc. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
6.2.4 Main Business/Business Overview
6.3 Biocon
6.3.2 Oncology Biosimilars Product Category, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Biocon Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
6.3.4 Main Business/Business Overview
6.4 BIOCAD
6.4.2 Oncology Biosimilars Product Category, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 BIOCAD Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
6.4.4 Main Business/Business Overview
6.5 Apotex Inc.
6.5.2 Oncology Biosimilars Product Category, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Apotex Inc. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
6.5.4 Main Business/Business Overview
6.6 Dr. Reddy's Laboratories Ltd.
6.6.2 Oncology Biosimilars Product Category, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 Dr. Reddy's Laboratories Ltd. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
6.6.4 Main Business/Business Overview
6.7 Sandoz International GmbH
6.7.2 Oncology Biosimilars Product Category, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 Sandoz International GmbH Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
6.7.4 Main Business/Business Overview
6.8 Intas Pharmaceuticals Ltd.
6.8.2 Oncology Biosimilars Product Category, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 Intas Pharmaceuticals Ltd. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
6.8.4 Main Business/Business Overview
6.9 STADA Arzneimittel AG
6.9.2 Oncology Biosimilars Product Category, Application and Specification
6.9.2.1 Product A
6.9.2.2 Product B
6.9.3 STADA Arzneimittel AG Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
6.9.4 Main Business/Business Overview
6.10 Teva Pharmaceutical Industries Ltd.
6.10.2 Oncology Biosimilars Product Category, Application and Specification
6.10.2.1 Product A
6.10.2.2 Product B
6.10.3 Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
6.10.4 Main Business/Business Overview
7 Oncology Biosimilars Manufacturing Cost Analysis
7.1 Oncology Biosimilars Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Oncology Biosimilars
8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Oncology Biosimilars Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Oncology Biosimilars Major Manufacturers in 2016
8.4 Downstream Buyers
9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List
10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change
11 United States Oncology Biosimilars Market Size (Value and Volume) Forecast (2017-2022)
11.1 United States Oncology Biosimilars Sales Volume, Revenue Forecast (2017-2022)
11.2 United States Oncology Biosimilars Sales Volume Forecast by Type (2017-2022)
11.3 United States Oncology Biosimilars Sales Volume Forecast by Application (2017-2022)
11.4 United States Oncology Biosimilars Sales Volume Forecast by Region (2017-2022)
12 Research Findings and Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
List of Tables and Figures
Figure Product Picture of Oncology Biosimilars
Figure United States Oncology Biosimilars Market Size (MT) by Type (2012-2022)
Figure United States Oncology Biosimilars Sales Volume Market Share by Type (Product Category) in 2016
Figure G-CSF Product Picture
Figure Hematopoietic Agents Product Picture
Figure Monoclonal Antibodies Product Picture
Figure United States Oncology Biosimilars Market Size (MT) by Application (2012-2022)
Figure United States Sales Market Share of Oncology Biosimilars by Application in 2016
Figure Retail Pharmacies Examples
Table Key Downstream Customer in Retail Pharmacies
Figure Hospital Pharmacies Examples
Table Key Downstream Customer in Hospital Pharmacies
Figure Online Pharmacies Examples
Table Key Downstream Customer in Online Pharmacies
Figure United States Oncology Biosimilars Market Size (Million USD) by Region (2012-2022)
Figure The West Oncology Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure Southwest Oncology Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Middle Atlantic Oncology Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure New England Oncology Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure The South of US Oncology Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure The Midwest Oncology Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Oncology Biosimilars Sales (MT) and Growth Rate (2012-2022)
Figure United States Oncology Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure United States Oncology Biosimilars Market Major Players Product Sales Volume (MT) (2012-2017)
Table United States Oncology Biosimilars Sales (MT) of Key Players/Suppliers (2012-2017)
Table United States Oncology Biosimilars Sales Share by Players/Suppliers (2012-2017)
Figure 2016 United States Oncology Biosimilars Sales Share by Players/Suppliers
Figure 2017 United States Oncology Biosimilars Sales Share by Players/Suppliers
Figure United States Oncology Biosimilars Market Major Players Product Revenue (Million USD) (2012-2017)
Table United States Oncology Biosimilars Revenue (Million USD) by Players/Suppliers (2012-2017)
Table United States Oncology Biosimilars Revenue Share by Players/Suppliers (2012-2017)
Figure 2016 United States Oncology Biosimilars Revenue Share by Players/Suppliers
Figure 2017 United States Oncology Biosimilars Revenue Share by Players/Suppliers
Table United States Market Oncology Biosimilars Average Price (USD/Kg) of Key Players/Suppliers (2012-2017)
Figure United States Market Oncology Biosimilars Average Price (USD/Kg) of Key Players/Suppliers in 2016
Figure United States Oncology Biosimilars Market Share of Top 3 Players/Suppliers
Figure United States Oncology Biosimilars Market Share of Top 5 Players/Suppliers
Table United States Players/Suppliers Oncology Biosimilars Manufacturing Base Distribution and Sales Area
Table United States Players/Suppliers Oncology Biosimilars Product Category
Table United States Oncology Biosimilars Sales (MT) by Region (2012-2017)
Table United States Oncology Biosimilars Sales Share by Region (2012-2017)
Figure United States Oncology Biosimilars Sales Share by Region (2012-2017)
Figure United States Oncology Biosimilars Sales Market Share by Region in 2016
Table United States Oncology Biosimilars Revenue (Million USD) and Market Share by Region (2012-2017)
Table United States Oncology Biosimilars Revenue Share by Region (2012-2017)
Figure United States Oncology Biosimilars Revenue Market Share by Region (2012-2017)
Figure United States Oncology Biosimilars Revenue Market Share by Region in 2016
Table United States Oncology Biosimilars Price (USD/Kg) by Region (2012-2017)
Table United States Oncology Biosimilars Sales (MT) by Type (2012-2017)
Table United States Oncology Biosimilars Sales Share by Type (2012-2017)
Figure United States Oncology Biosimilars Sales Share by Type (2012-2017)
Figure United States Oncology Biosimilars Sales Market Share by Type in 2016
Table United States Oncology Biosimilars Revenue (Million USD) and Market Share by Type (2012-2017)
Table United States Oncology Biosimilars Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Oncology Biosimilars by Type (2012-2017)
Figure Revenue Market Share of Oncology Biosimilars by Type in 2016
Table United States Oncology Biosimilars Price (USD/Kg) by Types (2012-2017)
Figure United States Oncology Biosimilars Sales Growth Rate by Type (2012-2017)
Table United States Oncology Biosimilars Sales (MT) by Application (2012-2017)
Table United States Oncology Biosimilars Sales Market Share by Application (2012-2017)
Figure United States Oncology Biosimilars Sales Market Share by Application (2012-2017)
Figure United States Oncology Biosimilars Sales Market Share by Application in 2016
Table United States Oncology Biosimilars Sales Growth Rate by Application (2012-2017)
Figure United States Oncology Biosimilars Sales Growth Rate by Application (2012-2017)
Table Celltrion Inc. Basic Information List
Table Celltrion Inc. Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Celltrion Inc. Oncology Biosimilars Sales Growth Rate (2012-2017)
Figure Celltrion Inc. Oncology Biosimilars Sales Market Share in United States (2012-2017)
Figure Celltrion Inc. Oncology Biosimilars Revenue Market Share in United States (2012-2017)
Table Pfizer Inc. Basic Information List
Table Pfizer Inc. Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Pfizer Inc. Oncology Biosimilars Sales Growth Rate (2012-2017)
Figure Pfizer Inc. Oncology Biosimilars Sales Market Share in United States (2012-2017)
Figure Pfizer Inc. Oncology Biosimilars Revenue Market Share in United States (2012-2017)
Table Biocon Basic Information List
Table Biocon Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Biocon Oncology Biosimilars Sales Growth Rate (2012-2017)
Figure Biocon Oncology Biosimilars Sales Market Share in United States (2012-2017)
Figure Biocon Oncology Biosimilars Revenue Market Share in United States (2012-2017)
Table BIOCAD Basic Information List
Table BIOCAD Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure BIOCAD Oncology Biosimilars Sales Growth Rate (2012-2017)
Figure BIOCAD Oncology Biosimilars Sales Market Share in United States (2012-2017)
Figure BIOCAD Oncology Biosimilars Revenue Market Share in United States (2012-2017)
Table Apotex Inc. Basic Information List
Table Apotex Inc. Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Apotex Inc. Oncology Biosimilars Sales Growth Rate (2012-2017)
Figure Apotex Inc. Oncology Biosimilars Sales Market Share in United States (2012-2017)
Figure Apotex Inc. Oncology Biosimilars Revenue Market Share in United States (2012-2017)
Table Dr. Reddy's Laboratories Ltd. Basic Information List
Table Dr. Reddy's Laboratories Ltd. Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Dr. Reddy's Laboratories Ltd. Oncology Biosimilars Sales Growth Rate (2012-2017)
Figure Dr. Reddy's Laboratories Ltd. Oncology Biosimilars Sales Market Share in United States (2012-2017)
Figure Dr. Reddy's Laboratories Ltd. Oncology Biosimilars Revenue Market Share in United States (2012-2017)
Table Sandoz International GmbH Basic Information List
Table Sandoz International GmbH Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Sandoz International GmbH Oncology Biosimilars Sales Growth Rate (2012-2017)
Figure Sandoz International GmbH Oncology Biosimilars Sales Market Share in United States (2012-2017)
Figure Sandoz International GmbH Oncology Biosimilars Revenue Market Share in United States (2012-2017)
Table Intas Pharmaceuticals Ltd. Basic Information List
Table Intas Pharmaceuticals Ltd. Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Intas Pharmaceuticals Ltd. Oncology Biosimilars Sales Growth Rate (2012-2017)
Figure Intas Pharmaceuticals Ltd. Oncology Biosimilars Sales Market Share in United States (2012-2017)
Figure Intas Pharmaceuticals Ltd. Oncology Biosimilars Revenue Market Share in United States (2012-2017)
Table STADA Arzneimittel AG Basic Information List
Table STADA Arzneimittel AG Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure STADA Arzneimittel AG Oncology Biosimilars Sales Growth Rate (2012-2017)
Figure STADA Arzneimittel AG Oncology Biosimilars Sales Market Share in United States (2012-2017)
Figure STADA Arzneimittel AG Oncology Biosimilars Revenue Market Share in United States (2012-2017)
Table Teva Pharmaceutical Industries Ltd. Basic Information List
Table Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Sales Growth Rate (2012-2017)
Figure Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Sales Market Share in United States (2012-2017)
Figure Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Revenue Market Share in United States (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Oncology Biosimilars
Figure Manufacturing Process Analysis of Oncology Biosimilars
Figure Oncology Biosimilars Industrial Chain Analysis
Table Raw Materials Sources of Oncology Biosimilars Major Players/Suppliers in 2016
Table Major Buyers of Oncology Biosimilars
Table Distributors/Traders List
Figure United States Oncology Biosimilars Sales Volume (MT) and Growth Rate Forecast (2017-2022)
Figure United States Oncology Biosimilars Revenue (Million USD) and Growth Rate Forecast (2017-2022)
Figure United States Oncology Biosimilars Price (USD/Kg) Trend Forecast (2017-2022)
Table United States Oncology Biosimilars Sales Volume (MT) Forecast by Type (2017-2022)
Figure United States Oncology Biosimilars Sales Volume (MT) Forecast by Type (2017-2022)
Figure United States Oncology Biosimilars Sales Volume (MT) Forecast by Type in 2022
Table United States Oncology Biosimilars Sales Volume (MT) Forecast by Application (2017-2022)
Figure United States Oncology Biosimilars Sales Volume (MT) Forecast by Application (2017-2022)
Figure United States Oncology Biosimilars Sales Volume (MT) Forecast by Application in 2022
Table United States Oncology Biosimilars Sales Volume (MT) Forecast by Region (2017-2022)
Table United States Oncology Biosimilars Sales Volume Share Forecast by Region (2017-2022)
Figure United States Oncology Biosimilars Sales Volume Share Forecast by Region (2017-2022)
Figure United States Oncology Biosimilars Sales Volume Share Forecast by Region in 2022
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
  • United States Adalimumab Biosimilar Market Report 2017
    Published: 17-Oct-2017        Price: US 3800 Onwards        Pages: 111
    In this report, the United States Adalimumab Biosimilar market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growth ra......
  • Global Biologics and Biosimilars Market Professional Survey Report 2017
    Published: 16-Oct-2017        Price: US 3500 Onwards        Pages: 112
    This report studies Biologics and Biosimilars in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top manufacturers in global market, with production, price, revenue and market share for each manufacturer, covering - Pfizer - Roche - Amgen - AbbVie - Sanofi - J......
  • Global Adalimumab Biosimilar Sales Market Report 2017
    Published: 13-Oct-2017        Price: US 4000 Onwards        Pages: 116
    In this report, the global Adalimumab Biosimilar market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Adalimumab Biosimilar for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe ......
  • The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis
    Published: 13-Oct-2017        Price: US 4000 Onwards        Pages: 104
    The U.S. psoriasis treatment market for Biologics and Biosimilars was estimated at $6.6bn in 2016 is projected to almost double during the forecast period to reach $12.9bn in 2021 driven by safety and efficacy improvements of the new generation biologics. The psoriasis treatment market is dominated by topical agents and photo therapy for the non-severe forms (mainly corticosteroids), but mild to severe forms are treated with systemic agents. The psoriasis treatment market is dominated......
  • Global Adalimumab Biosimilar Market Research Report 2017
    Published: 04-Oct-2017        Price: US 2900 Onwards        Pages: 112
    In this report, the global Adalimumab Biosimilar market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Adalimumab Biosimilar in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China......
  • Global Oncology Biosimilars Sales Market Report 2017
    Published: 28-Sep-2017        Price: US 4000 Onwards        Pages: 102
    In this report, the global Oncology Biosimilars market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (MT), revenue (Million USD), market share and growth rate of Oncology Biosimilars for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe - Japan......
  • United States Biologics and Biosimilars Market Report 2017
    Published: 22-Sep-2017        Price: US 3800 Onwards        Pages: 113
    In this report, the United States Biologics and Biosimilars market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report splits the United States market into seven regions: - The West - Southwest - The Middle Atlantic - New England - The South - The Midwest with sales (volume), revenue (value), market share and growt......
  • Global Biologics and Biosimilars Sales Market Report 2017
    Published: 19-Sep-2017        Price: US 4000 Onwards        Pages: 119
    In this report, the global Biologics and Biosimilars market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report split global into several key Regions, with sales (K Units), revenue (Million USD), market share and growth rate of Biologics and Biosimilars for these regions, from 2012 to 2022 (forecast), covering - United States - China - Europe......
  • Global Oncology Biosimilars Market Research Report 2017
    Published: 18-Sep-2017        Price: US 2900 Onwards        Pages: 100
    In this report, the global Oncology Biosimilars market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022. Geographically, this report is segmented into several key Regions, with production, consumption, revenue (million USD), market share and growth rate of Oncology Biosimilars in these regions, from 2012 to 2022 (forecast), covering - North America - Europe - China......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs